Tumor mutation burden as a marker for molecularly matched therapy: more evidence needed

被引：0
|
作者：
Meng, Xiang-Yu [1 ,2 ]
Wu, Qiu-Ji [3 ]
机构：
[1] Hubei Minzu Univ, Hlth Sci Ctr, Enshi 445000, Peoples R China
[2] Hubei Minzu Univ, Hubei Prov Key Lab Occurrence & Intervent Rheumat, Enshi 445000, Peoples R China
[3] Wuhan Univ, Zhongnan Hosp, Hubei Canc Clin Study Ctr, Dept Radiat & Med Oncol,Hubei Key Lab Tumour Biol, Wuhan 430071, Peoples R China
来源：
EPIGENOMICS | 2023年 / 15卷 / 22期
关键词：
biomarker; molecularly matched therapy; prognosis; targeted therapy; tumor mutation burden;
D O I：
10.2217/epi-2023-0354
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
引用
收藏
页码：1175 / 1178
页数：4
相关论文
共 12 条
  • [1] Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy
    Wang, Peipei
    Chen, Yueyun
    Wang, Chun
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [2] Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer
    Li, Yuan
    Chen, Zuhua
    Tao, Weiping
    Sun, Nan
    He, Jie
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (08) : 2367 - 2378
  • [3] Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer
    Yuan Li
    Zuhua Chen
    Weiping Tao
    Nan Sun
    Jie He
    Cancer Immunology, Immunotherapy, 2021, 70 : 2367 - 2378
  • [4] Tumor Mutation Score Is More Powerful Than Tumor Mutation Burden in Predicting Response to Immunotherapy in Non-Small Cell Lung Cancer
    Li, Y.
    Chen, Z.
    Wu, L.
    Tao, W.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S724 - S724
  • [5] High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy
    Sung, Ji-Youn
    Park, Dong-Won
    Lee, Seung-Hyeun
    BIOMEDICINES, 2022, 10 (09)
  • [6] Integrating angiogenesis signature and tumor mutation burden for improved patient stratification in immune checkpoint blockade therapy for muscle-invasive bladder cancer
    Shao, Fei
    Jin, Kaifeng
    Li, Bingyu
    Liu, Zhaopei
    Zeng, Han
    Wang, Yiwei
    Zhu, Yu
    Xu, Le
    Xu, Jiejie
    Wang, Zewei
    Chang, Yuan
    Zhang, Weijuan
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (10) : 433.e9 - 433.e18
  • [7] The landscape of gene mutations and clinical significance of tumor mutation burden in patients with soft tissue sarcoma who underwent surgical resection and received conventional adjuvant therapy
    Xu, Li-Bin
    Zhao, Zhen-Guo
    Xu, Song-Feng
    Zhang, Xin-Xin
    Liu, Ting
    Jing, Chang-You
    Zhang, Shu-Guang
    Yu, Sheng-Ji
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2020, 35 (03) : 14 - 22
  • [8] Combined Antiangiogenic Therapy and Immunotherapy Is Effective for Pancreatic Cancer With Mismatch Repair Proficiency but High Tumor Mutation Burden A Case Report
    Chen, Mengni
    Yang, Shengli
    Fan, Li
    Wu, Lu
    Chen, Renwang
    Chang, Jian
    Hu, Jianli
    PANCREAS, 2019, 48 (09) : 1232 - 1236
  • [9] High Tumor Mutation Burden Predicts Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinoma Treated With Targeted Therapy
    Lee, S. H.
    Sung, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S932 - S932
  • [10] A small amount of primary breast cancer shows high tumor mutation burden that may benefit from immune checkpoint inhibitor therapy
    Wang, J.
    Chen, W.
    Jiang, Z.
    Lin, X.
    Qin, T.
    Yang, X.
    Liu, T.
    Hu, H.
    Li, Z.
    Xie, D.
    Yao, H.
    Song, E.
    CANCER RESEARCH, 2019, 79 (04)
12